Deciphering targeting rules of splicing modulator compounds: case of TG003

BMC Molecular Biology

Masatoshi Hagiwara¹  Kei Iida¹  Maki Sakuma² 

[1] Medical Research Support Center, Kyoto University Graduate School of Medicine, Konoecho Yoshida Sakyo-ku, Kyoto 606-8501, Japan;Department of Anatomy and Developmental Biology, Kyoto University Graduate School of Medicine, Konoecho Yoshida Sakyo-ku, Kyoto 606-8501, Japan

关键词: Duchenne muscular dystrophy;    Polypyrimidine tract;    Splicing modulator;    Personalized medicine;    RNA-targeting therapy;    Virtual massive mutagenesis;    Comparative transcriptomics;    Comparative pharmacogenomics;   

Others  :  1227872
DOI  :  10.1186/s12867-015-0044-6

 received in 2015-04-13, accepted in 2015-09-11,  发布年份 2015

【 摘 要 】

Background

Recent advances in the development of small chemical compounds that can modulate RNA splicing brought excitement to the field of splicing-targeting therapy. Splicing-targeting therapy tries to ameliorate the disease by altering the exon combination of transcripts to reduce the undesired effect of genetic mutations. However, the knowledge and tools to understand factors contributing to splicing modulator compound sensitivity have been lacking. Our goal was to establish a method to characterize sequence features found in compound sensitive exons.

Results

Here we developed a comparative transcriptomic approach to explore features that make an exon sensitive to a chemical compound. In this study, we chose TG003, a potential drug for Duchenne muscular dystrophy, and performed RNA-sequencing on samples from human and mouse skeletal muscle cells, with and without TG003 treatments. We compared TG003 responsiveness between homologous exon pairs and identified 21 pairs in which human exons were skip-enhanced but not mouse exons. We compared the sequence features; splice site scores, number of splicing factor binding sites, and properties of branch sequence and polypyrimidine tracts, and found that polypyrimidine tracts were stronger (longer stretches and richer content of consecutive polypyrimidine) in the mouse TG003 insensitive exons. We also compared the features between TG003 skip-enhanced and insensitive exons within the species, and discovered that human TG003 skip-enhanced exons were shorter and had less splicing factor binding sites than the group of human TG003 insensitive exons. Mouse insensitive exons homologous to human TG003 skip-enhanced exons shared these properties. Our results suggested that these features are prerequisites for TG003 skip-enhanced exons and weak polypyrimidine tracts are defining features, which were supported by a decision tree analysis on all cassette exons in human.

Conclusions

In this study we established a comparative transcriptomic approach, which shed lights on how small chemical compounds modulate RNA splicing. The results described here was the first attempt to decipher the targeting rules of a splicing modulator compound. We expect that this approach would contribute to the precise understanding of the mechanism of TG003-induced splicing modulation, expand target diseases of splicing modulators in general, as well as the development of new splicing modulators.

【 授权许可】

   
2015 Sakuma et al.

【 图 表 】

Fig.1.

Fig.2.

Fig.3.

Fig.4.

Fig.5.

Fig.6.

Fig.7.

【 参考文献 】

• [1]Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008; 40(12):1413-1415.
• [2]Ogawa Y, Hagiwara M. Challenges to congenital genetic disorders with “RNA-targeting” chemical compounds. Pharmacol Ther. 2012; 134(3):298-305.
• [3]Ohe K, Hagiwara M. Modulation of alternative splicing with chemical compounds in new therapeutics for human diseases. ACS Chem Biol. 2015.
• [4]Spitali P, Aartsma-Rus A. Splice modulating therapies for human disease. Cell. 2012; 148(6):1085-1088.
• [5]Slaugenhaupt SA, Mull J, Leyne M, Cuajungco MP, Gill SP, Hims MM, Quintero F, Axelrod FB, Gusella JF. Rescue of a human mRNA splicing defect by the plant cytokinin kinetin. Hum Mol Genet. 2004; 13(4):429-436.
• [6]Yoshida M, Kataoka N, Miyauchi K, Ohe K, Iida K, Yoshida S, Nojima T, Okuno Y, Onogi H, Usui T et al: Rectifier of aberrant mRNA splicing recovers tRNA modification in familial dysautonomia. In: Proceedings of the National Academy of Sciences of the United States of America. 2015.
• [7]Naryshkin NA, Weetall M, Dakka A, Narasimhan J, Zhao X, Feng Z, Ling KK, Karp GM, Qi H, Woll MG et al.. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science. 2014; 345(6197):688-693.
• [8]Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, Holling T, Janson AA, Platenburg GJ, Sipkens JA et al.. Systemic administration of PRO051 in Duchenne’s muscular dystrophy. N Engl J Med. 2011; 364(16):1513-1522.
• [9]Dhir A, Buratti E. Alternative splicing: role of pseudoexons in human disease and potential therapeutic strategies. FEBS J. 2010; 277(4):841-855.
• [10]Muraki M, Ohkawara B, Hosoya T, Onogi H, Koizumi J, Koizumi T, Sumi K, Yomoda J, Murray MV, Kimura H et al.. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem. 2004; 279(23):24246-24254.
• [11]Nishida A, Kataoka N, Takeshima Y, Yagi M, Awano H, Ota M, Itoh K, Hagiwara M, Matsuo M. Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. Nat Commun. 2011; 2:308.
• [12]Yomoda J, Muraki M, Kataoka N, Hosoya T, Suzuki M, Hagiwara M, Kimura H. Combination of Clk family kinase and SRp75 modulates alternative splicing of Adenovirus E1A. Genes Cells. 2008; 13(3):233-244.
• [13]Prasad J, Manley JL. Regulation and substrate specificity of the SR protein kinase Clk/Sty. Mol Cell Biol. 2003; 23(12):4139-4149.
• [14]Aubol BE, Plocinik RM, Keshwani MM, McGlone ML, Hagopian JC, Ghosh G, Fu XD, Adams JA. N-terminus of the protein kinase CLK1 induces SR protein hyperphosphorylation. Biochem J. 2014; 462(1):143-152.
• [15]Ninomiya K, Kataoka N, Hagiwara M. Stress-responsive maturation of Clk1/4 pre-mRNAs promotes phosphorylation of SR splicing factor. J Cell Biol. 2011; 195(1):27-40.
• [16]Pandit S, Zhou Y, Shiue L, Coutinho-Mansfield G, Li H, Qiu J, Huang J, Yeo GW, Ares M, Fu XD. Genome-wide analysis reveals SR protein cooperation and competition in regulated splicing. Mol Cell. 2013; 50(2):223-235.
• [17]Anko ML, Muller-McNicoll M, Brandl H, Curk T, Gorup C, Henry I, Ule J, Neugebauer KM. The RNA-binding landscapes of two SR proteins reveal unique functions and binding to diverse RNA classes. Genome Biol. 2012; 13(3):R17. BioMed Central Full Text
• [18]Zhou Z, Fu XD. Regulation of splicing by SR proteins and SR protein-specific kinases. Chromosoma. 2013; 122(3):191-207.
• [19]Misteli T. RNA splicing: what has phosphorylation got to do with it? Curr Biol. 1999; 9(6):R198-R200.
• [20]Stamm S. Regulation of alternative splicing by reversible protein phosphorylation. J Biol Chem. 2008; 283(3):1223-1227.
• [21]Barbosa-Morais NL, Irimia M, Pan Q, Xiong HY, Gueroussov S, Lee LJ, Slobodeniuc V, Kutter C, Watt S, Colak R et al.. The evolutionary landscape of alternative splicing in vertebrate species. Science. 2012; 338(6114):1587-1593.
• [22]Goren A, Ram O, Amit M, Keren H, Lev-Maor G, Vig I, Pupko T, Ast G. Comparative analysis identifies exonic splicing regulatory sequences—the complex definition of enhancers and silencers. Mol Cell. 2006; 22(6):769-781.
• [23]Lareau LF, Inada M, Green RE, Wengrod JC, Brenner SE. Unproductive splicing of SR genes associated with highly conserved and ultra conserved DNA elements. Nature. 2007; 446(7138):926-929.
• [24]Katz Y, Wang ET, Airoldi EM, Burge CB. Analysis and design of RNA sequencing experiments for identifying isoform regulation. Nat Methods. 2010; 7(12):1009-1015.
• [25]Will CL, Luhrmann R. Spliceosome structure and function. Cold Spring Harb Perspect Biol. 2011; 3(7).
• [26]Hertel KJ. Combinatorial control of exon recognition. J Biol Chem. 2008; 283(3):1211-1215.
• [27]Smith CW, Valcarcel J. Alternative pre-mRNA splicing: the logic of combinatorial control. Trends Biochem Sci. 2000; 25(8):381-388.
• [28]Shao C, Yang B, Wu T, Huang J, Tang P, Zhou Y, Zhou J, Qiu J, Jiang L, Li H et al.. Mechanisms for U2AF to define 3′ splice sites and regulate alternative splicing in the human genome. Nat Struct Mol Biol. 2014; 21(11):997-1005.
• [29]Graveley BR, Hertel KJ, Maniatis T. The role of U2AF35 and U2AF65 in enhancer-dependent splicing. RNA. 2001; 7(6):806-818.
• [30]Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013; 14(4):R36. BioMed Central Full Text
• [31]Flicek P, Amode MR, Barrell D, Beal K, Billis K, Brent S, Carvalho-Silva D, Clapham P, Coates G, Fitzgerald S et al.. Ensembl 2014. Nucleic Acids Res. 2014; 42(Database issue):D749-D755.
• [32]Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB. Alternative isoform regulation in human tissue transcriptomes. Nature. 2008; 456(7221):470-476.
• [33]Coordinators NR. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2015; 43(Database issue):D6-D17.
• [34]Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997; 25(17):3389-3402.
• [35]Yeo G, Burge CB. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol. 2004; 11(2–3):377-394.
• [36]Piva F, Giulietti M, Nocchi L, Principato G. SpliceAid: a database of experimental RNA target motifs bound by splicing proteins in humans. Bioinformatics. 2009; 25(9):1211-1213.
• [37]Corvelo A, Hallegger M, Smith CWJ, Eyras E. Genome-Wide Association between Branch Point Properties and Alternative Splicing. Plos Comput Biol. 2010; 6(11).